Shifting Trends in the Indication of Glucagon-like Peptide-1 Receptor Agonist Prescriptions: A Nationwide Analysis

Ann Intern Med. 2024 Sep;177(9):1289-1291. doi: 10.7326/M24-0019. Epub 2024 Jul 23.

Authors

Yee Hui Yeo¹, Ali Rezaie¹, Tina Yi-Jin Hsieh², Xiaoqin Hu³, Srinivas Gaddam¹, Kevin Sheng-Kai Ma⁴; Gastrointestinal Motility and Metabolic Pharmacoepidemiology Group; Ghada Mohamed, Gin Yi Lee, Pin-Chia Huang, Rabindra Watson

Collaborators

Gastrointestinal Motility and Metabolic Pharmacoepidemiology Group:
Ghada Mohamed, Gin Yi Lee, Pin-Chia Huang, Rabindra Watson

Affiliations

¹ Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California.
² Department of Obstetrics & Gynecology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
³ Department of Infectious Diseases, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
⁴ Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

PMID: 39038291
DOI: 10.7326/M24-0019

No abstract available

Publication types

Letter

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Drug Prescriptions / statistics & numerical data
Glucagon-Like Peptide-1 Receptor Agonists*
Humans
Hypoglycemic Agents* / therapeutic use
Practice Patterns, Physicians' / trends
United States

Substances

Hypoglycemic Agents
Glucagon-Like Peptide-1 Receptor Agonists